FDA approves Defitelio for veno-occlusive disease following transplantation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease with additional kidney or lung abnormalities after hematopoietic stem cell transplantation. This is the first FDA-approved therapy for treatment of severe hepatic VOD. Hepatic VOD can occur in patients who receive chemotherapy and HSCT. The efficacy of Defitelio was investigated...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

ā€œBackwater to Blockbuster,ā€ the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants.  The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login